Home/Pipeline/AWT041

AWT041

Solid tumors

IND EnablingActive

Key Facts

Indication

Solid tumors

Phase

IND Enabling

Status

Active

Company

Anwita Biosciences

About Anwita Biosciences

Anwita Biosciences is a private, clinical-stage biotech leveraging an integrated technology platform for protein engineering to develop novel immunotherapies and targeted oncology treatments. Its lead asset, AWT020 (an anti-PD-1-IL-2 fusion protein), is in Phase 1 trials and has received FDA Orphan Drug Designation for thymic epithelial tumors. The company's strategy combines a deep biological understanding with rational engineering for selectivity and safety, supported by strategic partnerships and venture financing to advance its pipeline.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed